PTPI PETROS PHARMACEUTICALS INC

Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022

Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial Officer Fady Boctor will present virtually at the Planet MicroCap Showcase 2022. The conference is being held on May 3 – 5, 2022 at The Bally’s Hotel & Casino in Las Vegas, NV.

Presentation Date:May 4, 2022



Time:10:00am Pacific Time



Webcast Link:

Mr. Boctor will be available for one-on-one meetings. To request a meeting and to register for the conference, click here:

About Petros Pharmaceuticals

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.

CONTACTS:

Jules Abraham

CORE IR

917-885-7378



EN
28/04/2022

Underlying

PTPIPETROS PHARMACEUTICALS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PETROS PHARMACEUTICALS INC

 PRESS RELEASE
Free
PTPI PETROS PHARMACE...

Petros Pharmaceuticals Responds to Fraudulent Press Release

Petros Pharmaceuticals Responds to Fraudulent Press Release NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today confirmed that a press release issued on July 28, 2022 regarding a purported acquisition of the company was fraudulent and not issued by the Company. The Company is not a party to any such acquisition and has reported the fraudulent activity to Nasdaq. ABOUT PETROS PHARMACEUTICALS Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health co...

July 28, 2022 1 EN
 PRESS RELEASE
Free
PTPI PETROS PHARMACE...

Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity ...

Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky Dr. Drew to Raise Awareness of Petros Pharmaceuticals’ Mission in The Men’s Health Category and STENDRA® (avanafil) NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a compensated collaboration agreement with physician Dr. Drew Pinsky (“Dr. Drew”) to raise awareness, foster dialogue, educate, and alleviate the stigma of erectile dysfunction (ED) and sexual dysfunction...

July 19, 2022 1 EN
 PRESS RELEASE
Free
PTPI PETROS PHARMACE...

Petros Pharmaceuticals Reports First Quarter 2022 Financial Results an...

Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today announced financial results for the first quarter ended March 31, 2022. Recent Highlights: Announced the pursuit of the 505(b)(2) pathway for early stage asset, H-100 for the treatment of Peyronie’s DiseaseInitiated sponsored research agreement with Massachusetts General Hospital to evaluate incorporating the u...

May 16, 2022 1 EN
 PRESS RELEASE
Free
PTPI PETROS PHARMACE...

Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’...

Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease Which Impacts More Than 1 in 10 Men in the US Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local Medication Permeation Against Peyronie’s Disease, Which is Currently Predominantly Treated Surgically, or by a Series of Injections NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for ...

May 3, 2022 1 EN
 PRESS RELEASE
Free
PTPI PETROS PHARMACE...

Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022

Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022 NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial Officer Fady Boctor will present virtually at the Planet MicroCap Showcase 2022. The conference is being held on May 3 – 5, 2022 at The Bally’s Hotel & Casino in Las Vegas, NV. Presentation Date:May 4, 2022Time:10:00am Pacific TimeWebcast Link: Mr. Boctor will be available for one-on-one meetings. To request a meeting and to re...

April 28, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch